ALNYLAM PHARMACE.DL-,0001 revenue breakdown overview

ALNYLAM PHARMACE.DL-,0001 revenue for the last year amounted to 1.66 B EUR, the most of which — 1.66 B EUR — came from its highest performing source at the moment, Ribonucleic Acid Interference Therapeutics, the year earlier bringing 969.32 M EUR. The greatest contribution to the revenue figure was made by United States — last year it brought ALNYLAM PHARMACE.DL-,0001 1.16 B EUR, and the year before that — 575.30 M EUR.